

HESI Subcommittee on Risk Assessment for Sensitive Populations

Co-Chairs:

Ronald Hines, PhD

(Medical College of Wisconsin)

Dana Sargent, MS

(Bayer CropScience)

January 20, 2009, Emerging Issues Meeting
HESI Annual Meeting
Tucson, AZ



HESI Subcommittee on Risk Assessment for Sensitive Populations

- Spring 2006: Topic selected by HESI Emerging Issues Steering Committee
- Fall 2006: Subcommittee kick-off meeting
- Work product: Manuscript to be submitted for publication in peerreviewed journal



Mission

- Broaden and increase knowledge about the characterization of sensitive populations.
- Understand efforts to apply current and proposed methods for assessing risks to sensitive populations.
- Integrate results from applications and lessons learned to improve risk assessment for diverse sensitive populations in the future.



2008 Subcommittee Participation

<u>INDUSTRY</u>

3M Pharmaceuticals Bayer CropScience Dow AgroSciences Monsanto Company

PUBLIC

Alfred I. duPont Hospital for Children

European Food Safety Authority

Medical College of Wisconsin

Federal Institute for Drugs and Medical Devices (BfArM)

National Institutes of Health

National Cancer Institute

National Institute of Environmental Health Sciences

University of Washington

University of Aarhus, Denmark

US Environmental Protection Agency

National Center for Computational Toxicology

National Health and Environmental Effects Research

Laboratory

US Food and Drug Administration

Center for Drug Evaluation and Research

National Center for Toxicological Research



Manuscript

APPROACHES FOR ASSESSING RISKS TO SENSITIVE POPULATIONS: LESSONS LEARNED FROM EVALUATING RISKS IN THE PEDIATRIC POPULATION

Ronald N. Hines¹, Dana Sargent², Herman Autrup³, Linda S. Birnbaum⁴, Robert L. Brent⁵, Nancy G. Doerrer^{6*}, Elaine Cohen Hubal⁴, Daland R. Juberg⁷, Christian Laurent⁸, Robert Luebke⁴, Klaus Olejniczak⁹, Christopher J. Portier¹⁰, William Slikker¹¹

(targeted journal: Environmental Health Perspectives)



Scientific Manuscript: Four Fundamental Issues

- 1. Identification of critical biological, toxicological, and exposurerelated factors that should be examined when evaluating vulnerability (in this case, in the pediatric population).
- 2. Identification of methods, models, and experimental designs for evaluating pediatric populations which may be useful in evaluating other populations.
- 3. Identification of parameters unique to the pediatric population and that are not useful for extrapolating to other groups.
- 4. Identification of key gaps in the pediatric/vulnerability literature that should be addressed for pediatric and other potentially vulnerable groups.



Major Topics in Manuscript

H E S I

- Consideration of pediatric subjects as a sensitive population model when evaluating other potentially vulnerable groups
- Defining a sensitive population
- Relevant factors in the identification and assessment of sensitive populations (e.g., pharmacokinetics, pharmacodynamics, genetics, environmental exposure)
- Biomarkers of susceptibility
- Implementation of population-specific factors in risk assessment / modeling
- Discussion



Approach and Timeline

- July 2007 Subcommittee selected published literature for review.
- September 2007- Subcontractor was retained to review literature and produce summaries and commentaries regarding utility.
- **December 2007 Subcommittee developed a manuscript** outline.
- **January 2009** Manuscript completed and submitted for **HESI** peer review.
- February 2009 Manuscript submitted for publication in a scientific peer-reviewed journal (EHP).



Next Steps

- Sunset the Subcommittee after submission of manuscript to peer-reviewed journal (early 2009).
- The HESI Emerging Issues Steering Committee (EISC) could consider convening a more focused group on this topic when and if a proposal is submitted in future years through the annual emerging issues survey.